Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (not Insight Molecular Diagnostics Inc.) on October 17, 2018. The registrant is incorporated in California and is designated as an emerging growth company. The report addresses corporate governance and management matters, specifically executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a specific corporate event rather than a financial performance report.
Material Changes
The material change reported is the grant of stock options to an executive officer:
- Recipient: Lyndal Hesterberg, Senior Vice President of Research & Development.
- Grant Date: October 17, 2018.
- Quantity: 54,000 shares of common stock.
- Exercise Price: $1.95 per share (fair market value at grant).
- Plan: 2018 Equity Incentive Plan.
- Vesting Schedule: Three equal annual installments commencing on the first anniversary of the grant, conditioned on continuous service.
- Expiration: 10 years from the grant date, with accelerated expiration clauses for termination, death, or disability.
- Type: Incentive Stock Options (Section 422 of the Internal Revenue Code).
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements disclaiming any obligation to update future projections. It references the company's Form 10 for a detailed discussion of risk factors that could cause actual results to differ from anticipated results. No specific financial guidance or operational outlook is provided in this document.
Investor Verification Checklist
- Verify the correct registrant name is OncoCyte Corporation, not Insight Molecular Diagnostics Inc.
- Confirm the total number of shares authorized under the 2018 Equity Incentive Plan to assess dilution impact.
- Review the company's Form 10 for detailed risk factors and financial health metrics not included in this 8-K.
- Monitor the vesting schedule to understand future equity compensation expenses.